VIP (Vasoactive Intestinal Peptide).
28-aa peptide regulating immune, neural and vascular function.
Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.
- ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
- ✓Patient-named prescription only — dispensed against a valid Rx.
- ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
- ✓Cold-chain shipping across EU/EEA — 2–5 working days.
About VIP (Vasoactive Intestinal Peptide).
VIP is a 28-amino-acid neuropeptide and immune-system modulator with widespread effects on vascular tone, gut motility, lung function and neuroinflammation. It is studied in chronic inflammatory syndromes and biotoxin-related illnesses.
VIP is rapidly degraded; the magistral preparation is typically administered intranasally or via subcutaneous injection at frequent intervals.
VIP binds VPAC1 and VPAC2 receptors and signals via Gs-coupled cAMP pathways. It drives vasodilation, downregulates pro-inflammatory cytokines, modulates regulatory T-cell function and supports neurogenesis in the hippocampus.
Subcutaneous injection, typically 25–50 mcg, 1–4 times per day depending on indication.
Your physician sets the prescription. This is descriptive information, not a self-administration guide.
Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.
- INN / Name
- VIP (Vasoactive Intestinal Peptide)
- Form
- Lyophilised vial · subcutaneous injection
- Strength
- 10mg vial
- Manufacturing
- EU-GMP Annex 1 · Grade A/B
- Endotoxins
- European Pharmacopoeia 2.6.14 · LAL assay
- Identity & purity
- HPLC + MS · > 98%
- Cold chain
- Validated 2–8 °C, monitored end-to-end
- Regulatory basis
- Directive 2001/83/EC · Article 5(1)
2–5 working days
EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.
Magistral preparation
Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.
EU prescription recognition
Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.